Cannabis sativa

doi:10.1007/978-1-59259-887-8_2

Cited by 2 publications

(1 citation statement)

References 312 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cannabis sativa L. is a cosmopolitan, annual, dicotyledonous plant belonging to the Cannabaceae family, genus Cannabis (Farag & Kayser 2017). It has been cultivated for over 4,500 years and used in various fields such as medicine, food, textiles, and narcotics (Ross 2005). Research on Cannabis experienced exponential interest during the widespread use of the plant for recreational purposes in the 1960s-70s.…”

Section: Introductionmentioning

confidence: 99%

An ethnobotanical survey on the therapeutic use of Cannabis sativa L. in the province of Taounate, Morocco

Balafrej,

Skalli,

Benaich

et al. 2024

Ethnobot. Res. App.

View full text Add to dashboard Cite

Background: Cannabis has been used for over 4,500 years in different area, including medicine, to treat many illnesses. This study was to investigate to carry out an ethnobotanical survey to collect information on therapeutic uses of this plant by local population.Methods: Ethnobotanical study was conducted in Taounate province using semi-structured interviews with random informants. The data was analysed using statistical indices and tests as cultural Importance (CI), fidelity level (FL), relative frequency of citation (RFC), Chi square ( ) test, logistic regression, multiple corresponding analysis (MCA), and Non-metric multi-dimensional scaling (nMDS). Results: 65.4 % of the informants used Cannabis sativa L. Among them, therapeutic use showed a CI of 0.40. 11 diseases were found to be treated by cannabis. The most recommended preparation method was smoking, and the most common administration method was inhalation. Cham was the most cited ailment with a FL of 92.9 %. Results showed a significant correlation of therapeutic use with sex and type of locality. MCA revealed that people using cannabis for therapeutic use were sharing common trait with male, urban areas, secondary education level, and informants aged between 20 to 40 years. Then, Nmds showed that the treated disease were uniformly dispersed between rural and urban locality. cConclusion: The present study highlights the importance of therapeutic use of Cannabis sativa L. in Taounate province. However, more in-depth phytochemical, pharmacological, toxicological, and clinical research is needed to investigate its effectiveness and safety.

show abstract

Section: Introductionmentioning

confidence: 99%

An ethnobotanical survey on the therapeutic use of Cannabis sativa L. in the province of Taounate, Morocco

Balafrej,

Skalli,

Benaich

et al. 2024

Ethnobot. Res. App.

View full text Add to dashboard Cite

show abstract

Pharmacokinetics and pharmacodynamics of cannabis‐based medicine in a patient population included in a randomized, placebo‐controlled, clinical trial

Hansen,

Boix,

Hasselstrøm

et al. 2023

Clinical Translational Sci

View full text Add to dashboard Cite

Information on the pharmacokinetics (PK) and pharmacodynamics (PD) of orally administered cannabis‐based medicine (CBM) in capsule formulation in patient populations is sparse. In this exploratory study, we aimed to evaluate the PK and PD in a probable steady state of CBM in neuropathic pain and spasticity in a population of patients with multiple sclerosis (MS). Of 134 patients participating in a randomized, double‐blinded, placebo‐controlled, trial, 23 patients with MS (17 female) mean age 52 years (range 21–67) were enrolled in this substudy. They received oral capsules containing Δ9‐tetrahydrocannabinol (THC, n = 4), cannabidiol (CBD, n = 6), a combination (THC&CBD, n = 4), or placebo (n = 9). Maximum doses were 22.5 mg (THC) and 45 mg (CBD) a day divided into three administrations. PD parameters were evaluated for pain and spasticity. Blood samples were analyzed using an ultra‐high‐performance liquid chromatography–tandem mass spectrometer after protein precipitation and phospholipid removal. PK parameters were estimated using computerized modeling. The variation in daily dose and PK between individuals was considerable in a steady state, yet comparable with previous reports from healthy controls. Based on a simulation of the best model, the estimated PK parameters (mean) for THC (5 mg) were Cmax 1.21 ng/mL, Tmax 2.68 h, and half‐life 2.75 h, and for CBD (10 mg) were Cmax 2.67 ng/mL, Tmax 0.10 h, and half‐life 4.95 h, respectively. No effect was found on the PD parameters, but the placebo response was considerable. More immediate adverse events were registered in the active treatment groups compared with the placebo group.

show abstract

Cannabis sativa

Cited by 2 publications

References 312 publications

An ethnobotanical survey on the therapeutic use of Cannabis sativa L. in the province of Taounate, Morocco

An ethnobotanical survey on the therapeutic use of Cannabis sativa L. in the province of Taounate, Morocco

Pharmacokinetics and pharmacodynamics of cannabis‐based medicine in a patient population included in a randomized, placebo‐controlled, clinical trial

Contact Info

Product

Resources

About